β3-adrenergic receptor agonist
β3-adrenergic receptor agonist has been studied in 4 papers since 2018: none in people yet, 3 in animals, 1 review; 1 in the past year. The research so far is in animals. The newest paper, Oct 31, 2026: “From Cushion to Culprit: Pharmacological Reversal of Epicardial Adipose Tissue Remodeling in Obesity-Related Heart Failure with Preserved Ejection Fraction”.
4 papers study it5 findingsUpdated
1 new paper in 30 daysSee all 4
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Bristol Myers Squibb and 1 more
- Animals3
What did studies of β3-adrenergic receptor agonist find?
5Studies of β3-adrenergic receptor agonist measured 5 outcomes; the most studied are metabolic dysfunction-associated steatohepatitis (1 study), hepatocellular injury (1) and Nonalcoholic Fatty Liver Disease Activity Score (1).
Metabolic dysfunction-associated steatohepatitis
downin mice1
1 study
Metabolic dysfunction-associated steatohepatitis
downin mice1
β3-adrenergic receptor agonist decreases metabolic dysfunction-associated steatohepatitis in mice (addition to caloric restriction, compared with caloric restriction alone) (NASH pathology in 0/9 versus 8/10 mice).
“no (0/9) animals in this group fulfilled the criteria for NASH pathology compared to eight out of ten mice under caloric restriction alone.”
Animalsaddition to caloric restriction, compared with caloric restriction aloneliver
Laboratory investigation; a journal of technical methods and pathology
Hepatocellular injury
downin mice1
1 study
Hepatocellular injury
downin mice1
β3-adrenergic receptor agonist decreases hepatocellular injury in mice (addition to caloric restriction in mice with NASH).
“Addition of a β3AR agonist to mice subjected to caloric restriction enhanced weight loss and glucose tolerance, and improved liver steatosis, hepatocellular injury”
Animalsaddition to caloric restriction in mice with NASHliver
Laboratory investigation; a journal of technical methods and pathology
Nonalcoholic Fatty Liver Disease Activity Score
no changein mice1
1 study
Nonalcoholic Fatty Liver Disease Activity Score
no changein mice1
β3-adrenergic receptor agonist showed no clear effect on Nonalcoholic Fatty Liver Disease Activity Score in mice (high-fat diet-fed foz/foz mice with established NASH).
“but had no impact on liver inflammation or on nonalcoholic fatty liver disease activity score (NAS).”
Animalshigh-fat diet-fed foz/foz mice with established NASHliver
Laboratory investigation; a journal of technical methods and pathology
Hepatic lipid content
downin mice1
1 study
Hepatic lipid content
downin mice1
β3-adrenergic receptor agonist decreases hepatic lipid content in mice (high-fat diet-fed foz/foz mice with established NASH).
“treatment with β3AR agonist restored brown adipose tissue (BAT) function, decreased body weight, improved glucose tolerance, and reduced hepatic lipid content compared to untreated counterparts”
Animalshigh-fat diet-fed foz/foz mice with established NASHliver
Laboratory investigation; a journal of technical methods and pathology
Body weight
downin mice1
1 study
Body weight
downin mice1
β3-adrenergic receptor agonist decreases body weight in mice (high-fat diet-fed foz/foz mice with established NASH).
“treatment with β3AR agonist restored brown adipose tissue (BAT) function, decreased body weight, improved glucose tolerance, and reduced hepatic lipid content compared to untreated counterparts”
Animalshigh-fat diet-fed foz/foz mice with established NASH
Laboratory investigation; a journal of technical methods and pathology